China fears global trade isolation via Trump tariff deals
Ahead of a July 9 deadline, US officials are deep in talks with major trading partners in Asia and Europe, pushing for new agreements that would include restrictions on Chinese content, or secure commitments to counter what Washington sees as China's unfair trade practices.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, July 3, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," stock code: a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet medical needs, today announced that it has entered into a license and technology transfer agreement with Joincare Pharmaceutical Group Industry Co., Ltd ("Joincare Group"). Joincare Group will obtain an exclusive license from Brii Bio for the research, development, and commercialization of BRII-693 in the Greater China region. Under the terms of the agreement, Joincare Group will assume full responsibility for the development, regulatory approval and commercialization of BRII-693 in Greater China. In return, Brii Bio has received an upfront payment and will receive additional development and commercial milestone payments upon certain future milestone events plus tiered royalties on net product sales. BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with multidrug- and extensively drug-resistant (MDR/XDR) gram-negative bacterial infections, particularly those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA) and Enterobacterales (CRE). Discovered through iterative structural modifications of the polymyxin scaffold, BRII-693 was designed to enhance antibacterial potency while reducing the toxicity commonly associated with older polymyxin agents such as renal and neuro-toxicities. In phase 1 studies, BRII-693 demonstrated a favorable safety, tolerability, and PK profile in healthy non-Chinese and Chinese participants. Brii Bio received IND approval from CDE of NMPA for a Phase 1 PK bridging study in China supporting a future Phase 3 registrational trial in patients with hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Dr. Zhi Hong, Chairman and Chief Executive Officer of Brii Bio, commented: "The growing threat of antimicrobial resistance in Greater China underscores the urgency for novel hospital antibiotics. With Joincare Group's proven capabilities in manufacturing and commercializing hospital antibiotics, we found the ideal partner to accelerate the development and commercialization of BRII-693. This partnership enables us to deliver a critical care medicine to Chinese patients facing life threatening infections." Mr. Nanqi Lin, Chief Executive Officer of Joincare Group, stated, "The Company has a long-standing track record of excellence in innovative drug research and development, underpinned by deep scientific expertise and a robust R&D platform. Driven by Brii Bio's well-established R&D system, the BRII-693 project demonstrated strong innovation and scientific rigor. Early data showing encouraging results in terms of therapeutic potential, pharmacodynamics, and pharmacokinetics, suggesting BRII-693's high potential to become a best-in-class therapy to address the critical unmet clinical needs. We are confident in the clinical prospects of BRII-693. This collaboration further strengthened Joincare Group's strategic positioning in the anti-infection disease area. We look forward to launching this asset soon, providing patients with more high-quality treatment options." About BRII-693 BRII-693 is a novel synthetic lipopeptide in development for the treatment of critically ill patients with MDR/XDR gram-negative bacterial infections, especially carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Brii Bio holds exclusive global rights to develop and commercialize BRII-693. About Brii Bio Brii Biosciences Limited ("Brii Bio", stock code: is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. With a focus on infectious diseases, the Company is advancing a broad pipeline of unique therapeutic candidates with lead programs against hepatitis B virus (HBV) infection. The Company is led by a visionary and experienced leadership team and has operations in key biotech hubs, including Raleigh-Durham, the San Francisco Bay Area, Beijing and Shanghai. For more information, visit About Joincare Group Established in 1992, Joincare Group (Joincare Pharmaceutical Group Industry Co., Ltd) is an innovative scientific research-based integrated pharmaceutical group after many years of steady operation and rapid development. The group owns two major listed companies, Joincare and Livzon Pharmaceutical, as well as more than 20 major holding subsidiaries. The company has always adhered to the concept of scientific and technological innovation as the cornerstone, implementing a dual-driver strategy focused on innovative drugs and high-barrier complex formulation technology platforms, and has carried out rich pipeline layouts around respiratory, anti-infective, gastrointestinal, assisted reproduction, psychiatric, oncology and other areas of significant clinical needs, forming a rich and diversified product matrix and pipeline of drugs under development. Forward-looking Statements This contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance. View original content to download multimedia: SOURCE Brii Biosciences Limited
India.com
34 minutes ago
- India.com
Tibet Succession: China Rattled By Dalai Lama's Statement – What Did He Say?
New Delhi: Port-au-Prince silence. Lhasa anticipation. Beijing fury. One question set off a storm: Who will be the next Dalai Lama? The spiritual leader of Tibetan Buddhism has spoken. His words stirred a hornet's nest in China. During a recent address, the Dalai Lama made his intentions clear. No government would decide who succeeds him. No political hand would direct the future of his lineage. His successor would be chosen by monks. By the Gaden Phodrang Trust. By ancient rituals passed down over centuries. Not by state diktats or foreign interference. This message silenced speculation within the Tibetan community. For years, they had lived with uncertainty. Would the 600-year-old Dalai Lama institution continue? Would the chain of reincarnation end with him? The spiritual leader ended the doubt. The line will continue. The next Dalai Lama will be chosen. Tradition will guide the search. Faith will shape the future. China's reply came quickly and sharply. Foreign Ministry spokesperson Mao Ning told reporters in Beijing that the successor must be approved by China. She cited policies from the Qing dynasty era. Back then, top religious appointments needed imperial consent. That precedent, Beijing says, still stands. Without Chinese approval, there can be no legitimate spiritual authority, especially in Tibet. Mao Ning added that China respects religious freedom but only within the boundaries of the state. She emphasised the need for regulation. She said religious matters must stay under state control. This position clashed directly with the Dalai Lama's. He had firmly ruled out any government interference. No regime, no politician, no party. Only the Buddhist way. Back in Dharamshala, the Gaden Phodrang Trust confirmed the Dalai Lama had not yet given written instructions. Samdhong Rinpoche, a senior person in the trust, provided clarity. The successor could be male or female. Nationality would hold no weight. Tibetan roots would not be mandatory. Only spiritual merit would guide the choice. This week, the Dalai Lama turns 90. As the world celebrates his legacy, a new chapter looms. A chapter filled with questions. Who finds the next Lama? Who accepts him? Will there be one or two claimants? The clash is no longer spiritual alone. It is political and global. China wants control. Tibet wants continuity. And the world watches as the shadow of the future stretches across the mountains of Lhasa and the corridors of Beijing.
7NEWS
36 minutes ago
- 7NEWS
Chinese brand Zeekr eyes hybrids in Australian expansion
Zeekr wants to offer more than just electric vehicles (EVs) in Australia, with hybrid models firmly on the cards for a local launch. Just two models are currently offered Down Under – the 009 people mover and X compact SUV, both of which are EVs. The larger 7X electric SUV is due to arrive later this year, while a third SUV has been confirmed for 2026. The global lineup is also EV-heavy, although the Geely-owned Chinese carmaker is now venturing into the plug-in hybrid market with its new 9X large SUV. The Zeekr 9X features a 2.0-litre turbocharged four-cylinder petrol engine producing 205kW of power, mated with a 290kW front electric motor and a 370kW rear electric motor. Zeekr is also set to merge with fellow carmaker Lynk & Co, which specialises in hybrid and plug-in hybrid vehicles. Vehicles from the latter could come to Australia as soon as 2026, possibly wearing Zeekr badging as a means of expanding the reach of the challenger brand. Hundreds of new car deals are available through CarExpert right now. Get the experts on your side and score a great deal. Browse now. 'Under the new NVES we need to look at whether we'll be two entities or a single entity, what's better for us,' said Zeekr Australia head of product Melvyn Low. 'That's yet to be determined, whether it's another brand or a rebrand. It'll probably be a rebrand.' Cooling EV growth is one of the key drivers behind Zeekr's powertrain expansion, with the majority of Australian new car buyers still opting for internal combustion engine (ICE) or hybrid models. Zeekr's mid- to long-term strategy will also be informed by the impacts of the New Vehicle Efficiency Standard (NVES) – legislation designed to reduce the carbon footprint of the Australian car market. 'At the moment we have all BEVs. We know there may be customers that need a middle ground to transition (from ICE to EV) and our global brand offers a lot of powertrains, so I'm interested to see what other products we can bring with other powertrains in the future, ' said Mr Low. 'At the moment, we're understanding the market and where it's heading. Government incentives and what will happen in the future will influence our decisions as well.' While Zeekr has only just started to diversify its powertrain portfolio, the Australian arm will soon have more models to choose from. A second plug-in hybrid SUV is expected to launch alongside the 9X, with a global reveal set for late 2025. 'When introducing a new model to Australia in 2026, we need to look at the powertrain and segment,' Zeekr global product marketing director Tony Zhou told CarExpert. 'We have a compact SUV, C/D segment SUV, and MPV, what will be next… is under discussion. We have BEV, big SUV, small SUV, hatchbacks, hybrids and PHEVs in our pocket.'
